Benitec Biopharma Files 8-K Report
Ticker: BNTC · Form: 8-K · Filed: Apr 18, 2024 · CIK: 1808898
| Field | Detail |
|---|---|
| Company | Benitec Biopharma INC. (BNTC) |
| Form Type | 8-K |
| Filed Date | Apr 18, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 B |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, financials, sec-disclosure
TL;DR
Benitec Biopharma filed an 8-K, check for new disclosures.
AI Summary
On April 18, 2024, Benitec Biopharma Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, and includes a Regulation FD Disclosure. No specific financial figures or material events beyond the filing itself are detailed in the provided text.
Why It Matters
This filing indicates that Benitec Biopharma Inc. is providing updated information to the SEC, which could include financial statements or other material disclosures relevant to investors.
Risk Assessment
Risk Level: low — The filing is a standard procedural report and does not disclose any immediate negative events or significant financial changes.
Key Numbers
- 001-39267 — Commission File Number (Identifies the company's SEC filing history.)
- 84-4620206 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Benitec Biopharma Inc. (company) — Registrant
- April 18, 2024 (date) — Date of Report
- 001-39267 (company) — Commission File Number
- Hayward, California (location) — Principal Executive Offices
FAQ
What specific items are included in the 8-K filing?
The filing explicitly mentions 'Financial Statements and Exhibits' and 'Regulation FD Disclosure' as items included.
When was this 8-K report filed?
The report was filed on April 18, 2024.
What is the principal executive office address for Benitec Biopharma Inc.?
The principal executive offices are located at 3940 Trust Way, Hayward, California 94545.
What is the Commission File Number for Benitec Biopharma Inc.?
The Commission File Number is 001-39267.
What is the Standard Industrial Classification (SIC) code for Benitec Biopharma Inc.?
The SIC code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 561 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2024-04-18 08:53:27
Key Financial Figures
- $0.0001 B — ich registered Common Stock, par value $0.0001 BNTC The Nasdaq Stock Market LLC Indic
Filing Documents
- d815188d8k.htm (8-K) — 25KB
- d815188dex991.htm (EX-99.1) — 16KB
- d815188dex992.htm (EX-99.2) — 70KB
- g815188dsp5.jpg (GRAPHIC) — 6KB
- g815188dsp7.jpg (GRAPHIC) — 116KB
- g815188testp10g1.jpg (GRAPHIC) — 260KB
- g815188testp11g1.jpg (GRAPHIC) — 265KB
- g815188testp12g1.jpg (GRAPHIC) — 246KB
- g815188testp13g1.jpg (GRAPHIC) — 263KB
- g815188testp14g1.jpg (GRAPHIC) — 90KB
- g815188testp15g1.jpg (GRAPHIC) — 256KB
- g815188testp16g1.jpg (GRAPHIC) — 194KB
- g815188testp17g1.jpg (GRAPHIC) — 200KB
- g815188testp18g1.jpg (GRAPHIC) — 269KB
- g815188testp19g1.jpg (GRAPHIC) — 183KB
- g815188testp1g1.jpg (GRAPHIC) — 239KB
- g815188testp20g1.jpg (GRAPHIC) — 437KB
- g815188testp21g1.jpg (GRAPHIC) — 444KB
- g815188testp22g1.jpg (GRAPHIC) — 286KB
- g815188testp23g1.jpg (GRAPHIC) — 273KB
- g815188testp24g1.jpg (GRAPHIC) — 242KB
- g815188testp25g1.jpg (GRAPHIC) — 261KB
- g815188testp26g1.jpg (GRAPHIC) — 318KB
- g815188testp27g1.jpg (GRAPHIC) — 253KB
- g815188testp28g1.jpg (GRAPHIC) — 422KB
- g815188testp29g1.jpg (GRAPHIC) — 351KB
- g815188testp2g1.jpg (GRAPHIC) — 579KB
- g815188testp30g1.jpg (GRAPHIC) — 234KB
- g815188testp31g1.jpg (GRAPHIC) — 457KB
- g815188testp32g1.jpg (GRAPHIC) — 257KB
- g815188testp33g1.jpg (GRAPHIC) — 267KB
- g815188testp34g1.jpg (GRAPHIC) — 264KB
- g815188testp35g1.jpg (GRAPHIC) — 321KB
- g815188testp36g1.jpg (GRAPHIC) — 276KB
- g815188testp37g1.jpg (GRAPHIC) — 439KB
- g815188testp38g1.jpg (GRAPHIC) — 211KB
- g815188testp39g1.jpg (GRAPHIC) — 326KB
- g815188testp3g1.jpg (GRAPHIC) — 123KB
- g815188testp40g1.jpg (GRAPHIC) — 232KB
- g815188testp41g1.jpg (GRAPHIC) — 241KB
- g815188testp42g1.jpg (GRAPHIC) — 223KB
- g815188testp43g1.jpg (GRAPHIC) — 217KB
- g815188testp44g1.jpg (GRAPHIC) — 347KB
- g815188testp45g1.jpg (GRAPHIC) — 343KB
- g815188testp46g1.jpg (GRAPHIC) — 240KB
- g815188testp47g1.jpg (GRAPHIC) — 247KB
- g815188testp48g1.jpg (GRAPHIC) — 208KB
- g815188testp49g1.jpg (GRAPHIC) — 251KB
- g815188testp4g1.jpg (GRAPHIC) — 261KB
- g815188testp50g1.jpg (GRAPHIC) — 353KB
- g815188testp51g1.jpg (GRAPHIC) — 340KB
- g815188testp52g1.jpg (GRAPHIC) — 187KB
- g815188testp53g1.jpg (GRAPHIC) — 314KB
- g815188testp54g1.jpg (GRAPHIC) — 324KB
- g815188testp55g1.jpg (GRAPHIC) — 255KB
- g815188testp56g1.jpg (GRAPHIC) — 277KB
- g815188testp57g1.jpg (GRAPHIC) — 277KB
- g815188testp58g1.jpg (GRAPHIC) — 140KB
- g815188testp59g1.jpg (GRAPHIC) — 299KB
- g815188testp5g1.jpg (GRAPHIC) — 315KB
- g815188testp60g1.jpg (GRAPHIC) — 331KB
- g815188testp61g1.jpg (GRAPHIC) — 327KB
- g815188testp62g1.jpg (GRAPHIC) — 218KB
- g815188testp63g1.jpg (GRAPHIC) — 308KB
- g815188testp64g1.jpg (GRAPHIC) — 375KB
- g815188testp65g1.jpg (GRAPHIC) — 161KB
- g815188testp66g1.jpg (GRAPHIC) — 82KB
- g815188testp67g1.jpg (GRAPHIC) — 138KB
- g815188testp68g1.jpg (GRAPHIC) — 128KB
- g815188testp69g1.jpg (GRAPHIC) — 118KB
- g815188testp6g1.jpg (GRAPHIC) — 417KB
- g815188testp70g1.jpg (GRAPHIC) — 125KB
- g815188testp71g1.jpg (GRAPHIC) — 235KB
- g815188testp7g1.jpg (GRAPHIC) — 316KB
- g815188testp8g1.jpg (GRAPHIC) — 215KB
- g815188testp9g1.jpg (GRAPHIC) — 447KB
- 0001193125-24-100080.txt ( ) — 27065KB
- bntc-20240418.xsd (EX-101.SCH) — 3KB
- bntc-20240418_lab.xml (EX-101.LAB) — 17KB
- bntc-20240418_pre.xml (EX-101.PRE) — 11KB
- d815188d8k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BENITEC BIOPHARMA INC. Date: April 18, 2024 /s/ Jerel A. Banks Name: Jerel A. Banks Title: Chief Executive Officer